WallStreetZenWallStreetZen

NASDAQ: ACOR
Acorda Therapeutics Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

ACOR past revenue growth

How has ACOR's revenue growth performed historically?
Company
-3.63%
Industry
69.54%
Market
14.01%
ACOR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ACOR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ACOR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ACOR earnings and revenue history

Current Revenue
$118.3M
Current Earnings
-$58.2M
Current Profit Margin
-49.2%

ACOR Return on Equity

Current Company
-69.7%
Current Industry
-18%
Current Market
30.8%
ACOR's Return on Equity (-69.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ACOR announces earnings.

ACOR Return on Assets

Current Company
-14.8%
Current Industry
0.9%
ACOR is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ACOR Return on Capital Employed

Current Company
0.11%
Current Industry
14.1%
ACOR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ACOR vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ACOR$118.29M$32.55M-$58.22M-27.11%N/A
IBIO$61.00k-$73.71M-$76.03M-34.34%N/A
DOMH$0.00-$22.42M-$23.43M-100.00%N/A
BWV$0.00-$14.19M-$14.20MN/AN/A
CING$0.00-$16.11M-$16.68MN/AN/A
View Top Biotech Stocks

ACOR earnings dates

Next earnings date
Aug 2, 2023

Acorda Therapeutics Earnings & Revenue FAQ

What were ACOR's earnings last quarter?

On Invalid Date, Acorda Therapeutics (NASDAQ: ACOR) reported Q1 2023 earnings per share (EPS) of -$0.69, up 62.7% year over year. Total Acorda Therapeutics earnings for the quarter were -$16.82 million. In the same quarter last year, Acorda Therapeutics's earnings per share (EPS) was -$1.85.

If you're new to stock investing, here's how to buy Acorda Therapeutics stock.

What was ACOR's earnings growth in the past year?

As of Q2 2023, Acorda Therapeutics's earnings has grown year over year. Acorda Therapeutics's earnings in the past year totalled -$58.22 million.

What is ACOR's earnings date?

Acorda Therapeutics's earnings date is Invalid Date. Add ACOR to your watchlist to be reminded of ACOR's next earnings announcement.

What was ACOR's revenue last quarter?

On Invalid Date, Acorda Therapeutics (NASDAQ: ACOR) reported Q1 2023 revenue of $22.26 million up 1.22% year over year. In the same quarter last year, Acorda Therapeutics's revenue was $22.53 million.

What was ACOR's revenue growth in the past year?

As of Q2 2023, Acorda Therapeutics's revenue has grown -3.63% year over year. This is 73.16 percentage points lower than the US Biotechnology industry revenue growth rate of 69.54%. Acorda Therapeutics's revenue in the past year totalled $118.29 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.